Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204355 · ClinicalTrials.gov registry record
MRI for Screening and Monitoring Scleroderma ILD
A clinical trial of Scleroderma, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT05204355: Active study of Scleroderma, sponsored by University of Kansas Medical Center.
NCT05204355 is a study of Scleroderma that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 25 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05204355, a study of Scleroderma, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
Primary Outcome
An experienced radiologist will review MRI and CT images to assess whether ILD is present.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
- DRUG Hyperpolarized Xe129
- DIAGNOSTIC_TEST HRCT
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2025-10-31 |
What the registry record for NCT05204355 still lists
NCT05204355 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.
NCT05204355 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05204355 about?
NCT05204355 is a clinical study titled "MRI for Screening and Monitoring Scleroderma ILD". The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
What is the current status of trial NCT05204355?
This trial is currently active not recruiting. The enrollment target is 25 participants. The study started on 2022-05-01. Estimated completion is 2025-10-31.
What conditions does trial NCT05204355 study?
This clinical trial studies the following conditions: Scleroderma.
What interventions are being tested in trial NCT05204355?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Hyperpolarized Xe129 (DRUG), HRCT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05204355?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05204355 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05204355's enrollment target sits among peer trials
25 19th of 23 higher than 5 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI